Federal Court Rejects Bid to Block DEA Cannabis Rescheduling

Court Denies Emergency Injunction Request

The federal court found petitioners failed to demonstrate irreparable harm sufficient to warrant an emergency injunction blocking the DEA rescheduling process. The motion, filed by coalition groups including Smart Approaches to Marijuana (SAM) and other opponents of cannabis reform, sought immediate relief to prevent the DEA from publishing a final rule moving marijuana to Schedule III under 21 U.S.C. § 812.

Courts typically require a showing of likelihood of success on the merits, irreparable injury, balance of hardships favoring the movant, and public interest alignment. The September 9 order concluded petitioners hadn't met that standard.

The ruling doesn't address the underlying merits of the rescheduling itself. It denies the request to pause the administrative process while legal challenges proceed.

DEA Rescheduling Timeline Remains on Track

The Drug Enforcement Administration can now continue finalizing its Notice of Proposed Rulemaking without court-imposed delay. The DEA published its proposed rule to move cannabis to Schedule III in May 2024, following a recommendation from the Department of Health and Human Services based on a scientific review conducted under the Trump administration's directive.

Public comment periods and administrative law judge hearings are complete. The denial clears one procedural obstacle. Opponents retain the right to challenge a final rule once it's published in the Federal Register.

Industry observers expect the DEA to publish a final rule before the end of 2026, though the agency hasn't confirmed a specific timeline.

What Schedule III Means for Cannabis Operators

Rescheduling to Schedule III would eliminate the 280E tax penalty that currently prevents state-licensed cannabis businesses from deducting ordinary business expenses. Under Internal Revenue Code Section 280E, companies trafficking in Schedule I or II controlled substances can't claim federal tax deductions for rent, payroll, marketing, or other operating costs—only cost of goods sold.

Moving cannabis to Schedule III would allow multi-state operators to deduct millions in expenses, fundamentally altering the economics of legal cannabis.

The change wouldn't legalize cannabis federally. It wouldn't resolve state-federal conflicts over adult-use programs. Schedule III drugs remain controlled substances subject to DEA registration requirements and prescribing restrictions. But the tax relief would materially improve cash flow for licensed operators, particularly multi-state operators carrying significant tax liabilities.

Opponents Argue Rescheduling Violates Treaty Obligations

Petitioners said the rescheduling violates international treaty obligations under the Single Convention on Narcotic Drugs of 1961. The coalition said that moving cannabis to Schedule III contradicts U.S. commitments under international drug control treaties, which classify cannabis as having no accepted medical use.

The court's denial of the injunction doesn't resolve this argument. Opponents can raise treaty-based and other substantive objections in formal comments and in challenges to a final rule under the Administrative Procedure Act. APA challenges typically focus on whether an agency acted arbitrarily, capriciously, or contrary to law.

Legal experts note that courts generally defer to executive branch interpretations of treaty obligations. The U.S. has previously reconciled state cannabis programs with treaty commitments through federalism arguments.

What Happens Next in the Rescheduling Process

The DEA must review the administrative record, including public comments and hearing testimony, before publishing a final rule. Once a final rule is published, opponents have 60 days to file petitions for review in federal appellate court. Any legal challenge would proceed on the merits of the agency's scientific and legal conclusions, not on emergency procedural grounds.

For full background on this process, see the CannIntel topic hub on DEA rescheduling. The hub tracks key filings, comment periods, and industry impact analysis as the rule moves toward finalization.

We'll be watching whether the DEA publishes a final rule before year-end or extends the timeline into 2027. Industry groups and state regulators are watching for guidance on how Schedule III classification will interact with existing state licensing frameworks.